Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

6.400 -0.200 (-3.03%)
Streaming Delayed Price Updated: 11:27 AM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 598,663
Open 6.570
Bid (Size) 6.390 (2)
Ask (Size) 6.410 (2)
Prev. Close 6.600
Today's Range 6.390 - 6.600
52wk Range 3.980 - 23.40
Shares Outstanding 45,711,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits
From Bragar Eagel & Squire
Via GlobeNewswire
CAPR INVESTORS: Kirby McInerney LLP Reminds Capricor Therapeutics, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm
From Kirby McInerney LLP
Via Business Wire

Performance

YTD
-57.2%
-57.2%
1 Month
-5.7%
-5.7%
3 Month
-38.9%
-38.9%
6 Month
-55.7%
-55.7%
1 Year
+30.9%
+30.9%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
Shareholders of Capricor Therapeutics, Inc. Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR
Via TheNewswire.com
Topics Fraud Lawsuit
Shareholders of Capricor Therapeutics, Inc. Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR
Via NewMediaWire
Topics Fraud Lawsuit
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR)
From Bernstein Liebhard LLP
Via GlobeNewswire
September 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CAPR
Via NewMediaWire
Topics Fraud Lawsuit
September 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CAPR
Via TheNewswire.com
Topics Fraud Lawsuit
Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting
Via Benzinga
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR
Via TheNewswire.com
Topics Fraud Lawsuit
CAPR Investors Have the Opportunity to Lead the Capricor Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
September 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CAPR
Via TheNewswire.com
Topics Fraud Lawsuit
September 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CAPR
Via NewMediaWire
Topics Fraud Lawsuit
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR
Via NewMediaWire
Topics Fraud Lawsuit
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR
Via TheNewswire.com
Topics Fraud Lawsuit
Shareholders of Capricor Therapeutics, Inc. Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR
Via NewMediaWire
Topics Fraud Lawsuit
Shareholders of Capricor Therapeutics, Inc. Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR
Via TheNewswire.com
Topics Fraud Lawsuit
SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR)
From Bernstein Liebhard LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. – CAPR
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR
From The Rosen Law Firm PA
Via GlobeNewswire
Investors in Capricor Therapeutics, Inc. Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR
Via TheNewswire.com
Topics Fraud Lawsuit

Frequently Asked Questions

Is Capricor Therapeutics, Inc. - Common Stock publicly traded?
Yes, Capricor Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Capricor Therapeutics, Inc. - Common Stock trade on?
Capricor Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Capricor Therapeutics, Inc. - Common Stock?
The ticker symbol for Capricor Therapeutics, Inc. - Common Stock is CAPR on the Nasdaq Stock Market
What is the current price of Capricor Therapeutics, Inc. - Common Stock?
The current price of Capricor Therapeutics, Inc. - Common Stock is 6.400
When was Capricor Therapeutics, Inc. - Common Stock last traded?
The last trade of Capricor Therapeutics, Inc. - Common Stock was at 08/26/25 11:27 AM ET
What is the market capitalization of Capricor Therapeutics, Inc. - Common Stock?
The market capitalization of Capricor Therapeutics, Inc. - Common Stock is 292.56M
How many shares of Capricor Therapeutics, Inc. - Common Stock are outstanding?
Capricor Therapeutics, Inc. - Common Stock has 293M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.